The clinical use of colistin in patients with cystic fibrosis
- PMID: 11706322
- DOI: 10.1097/00063198-200111000-00013
The clinical use of colistin in patients with cystic fibrosis
Abstract
Colistin is a cationic polypeptide antibiotic from the polymyxin family that was first introduced in 1962 but abandoned in the early 1970s because of initial reports of severe toxicities. However, a recent increase in the prevalence of multidrug resistant (MDR) Pseudomonas aeruginosa and the lack of novel agents in development calls for a need to re-examine the role of colistin therapy in patients with cystic fibrosis. Current data supports the use of intravenous colistimethate for the treatment of acute pulmonary exacerbations involving MDR P. aeruginosa and inhaled therapy for initial colonization. The frequency of nephrotoxicity and severity of neurotoxicity seem to be substantially less than previously believed. In addition, recent pharmacokinetic and pharmacodynamic data suggests new intravenous dosing regimens may enhance efficacy while minimizing toxicities; such regimens deserve further evaluation. Pre- and post-treatment spirometry is recommended at initiation of inhaled colistin therapy to identify sensitized individuals. Judicious use of colistin where the benefits have been clearly documented will retain this as a useful agent in the management of P. aeruginosa infections in patients with cystic fibrosis.
Similar articles
-
[Practical guideline for the use of colistin].Ned Tijdschr Geneeskd. 2014;158:A7445. Ned Tijdschr Geneeskd. 2014. PMID: 25322351 Review. Dutch.
-
[Inhaled colistin in cystic fibrosis].Schweiz Med Wochenschr. 2000 Sep 30;130(39):1366-72. Schweiz Med Wochenschr. 2000. PMID: 11059027 Clinical Trial. German.
-
PhoQ mutations promote lipid A modification and polymyxin resistance of Pseudomonas aeruginosa found in colistin-treated cystic fibrosis patients.Antimicrob Agents Chemother. 2011 Dec;55(12):5761-9. doi: 10.1128/AAC.05391-11. Epub 2011 Oct 3. Antimicrob Agents Chemother. 2011. PMID: 21968359 Free PMC article.
-
Intravenous colistin sulphomethate in acute respiratory exacerbations in adult patients with cystic fibrosis.Thorax. 1997 Nov;52(11):987-93. doi: 10.1136/thx.52.11.987. Thorax. 1997. PMID: 9487348 Free PMC article. Clinical Trial.
-
Colistin in multi-drug resistant Pseudomonas aeruginosa blood-stream infections: a narrative review for the clinician.J Infect. 2014 Jul;69(1):1-12. doi: 10.1016/j.jinf.2014.03.001. Epub 2014 Mar 11. J Infect. 2014. PMID: 24631777 Review.
Cited by
-
Liposomal Formulation Reduces Transport and Cell Uptake of Colistin in Human Lung Epithelial Calu-3 Cell and 3D Human Lung Primary Tissue Models.AAPS PharmSciTech. 2024 Feb 17;25(3):40. doi: 10.1208/s12249-024-02753-6. AAPS PharmSciTech. 2024. PMID: 38366100
-
Characterization and Inhibition of 1-Deoxy-d-Xylulose 5-Phosphate Reductoisomerase: A Promising Drug Target in Acinetobacter baumannii and Klebsiella pneumoniae.ACS Infect Dis. 2021 Nov 12;7(11):2987-2998. doi: 10.1021/acsinfecdis.1c00132. Epub 2021 Oct 21. ACS Infect Dis. 2021. PMID: 34672535 Free PMC article.
-
Colistin neurotoxicity mimicking Guillain-Barré syndrome in a patient with cystic fibrosis: case report and review.Oxf Med Case Reports. 2021 Sep 13;2021(9):omab080. doi: 10.1093/omcr/omab080. eCollection 2021 Sep. Oxf Med Case Reports. 2021. PMID: 34527253 Free PMC article.
-
Evaluation of Chemical Changes in Laboratory-Induced Colistin-Resistant Klebsiella pneumoniae.Int J Mol Sci. 2021 Jul 1;22(13):7104. doi: 10.3390/ijms22137104. Int J Mol Sci. 2021. PMID: 34281159 Free PMC article.
-
SARS-CoV-2 RNA Dependent RNA polymerase (RdRp) - A drug repurposing study.Heliyon. 2020 Jul 23;6(7):e04502. doi: 10.1016/j.heliyon.2020.e04502. eCollection 2020 Jul. Heliyon. 2020. PMID: 32754651 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
